FDA extends review of Orca Bio's Orca-T for hematologic malignancies to July 2026

Orca Bio has announced that the US FDA extended the review timeline for its Biologics License Application (BLA) for Orca-T, an investigational allogeneic T-cell immunotherapy targeting hematologic malignancies including acute leukemias and myelodysplastic syndromes. The revised PDUFA target action date is July 6, 2026, three months beyond the original deadline, following the FDA's classification of a recent company submission as a Major Amendment to the BLA. The extension was triggered by Orca Bio's submission of updated chemistry, manufacturing and controls (CMC) information provided in response to FDA requests during the standard review process, the company [said](https://www.businesswire.com/news/home/20260401769347/en/Orca-Bio-Announces-FDA-Review-Extension-of-BLA-for-Orca-T-for-the-Treatment-of-Hematologic-Malignancies). The agency has not requested additional clinical data, and Orca Bio stated it believes the updated CMC information does not affect the benefit-risk conclusions of the BLA. The filing carries Priority Review designation, and Orca-T has previously received Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation for the prevention of graft-versus-host disease (GVHD) or death in patients eligible for hematopoietic stem cell transplant (HSCT). Orca-T is composed of highly purified hematopoietic stem cells, regulatory T-cells, and conventional T-cells derived from matched related or unrelated donors. The inclusion of regulatory T-cells is central to the product's design rationale: by modulating the post-transplant alloreactive immune response, the approach aims to reduce GVHD without eliminating the graft-versus-leukemia effect that makes allogeneic transplantation therapeutically relevant. This positions Orca-T not as an adjunctive drug but as a redefined graft — intended to replace conventional unmanipulated cell products at the transplant step itself. The clinical program supporting the BLA includes the Phase III [Precision-T trial (NCT05316701)](https://clinicaltrials.gov/study/NCT05316701), which enrolled patients with hematologic malignancies and used moderate or severe chronic GVHD-free survival at 12 months as its primary endpoint, assessed by an independent Endpoint Adjudication Committee. An earlier [Phase Ib study (NCT04013685)](https://clinicaltrials.gov/study/NCT04013685) focused on safety endpoints including the incidence of grade 3 or 4 acute GVHD and primary graft failure. The filing enters review at a time when GVHD remains a substantial source of morbidity and non-relapse mortality in the allogeneic transplant setting. Approved prophylactic agents include abatacept, which received FDA approval in 2021 for use in unrelated-donor transplants, while treatment options for established GVHD include ruxolitinib, belumosudil, and axatilimab, the latter approved in 2024 for recurrent or refractory chronic GVHD. Despite these additions, no approved intervention has demonstrated the capacity to simultaneously reduce GVHD and preserve the graft-versus-leukemia effect — the core biological tension that precision graft engineering approaches such as Orca-T are designed to address. --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/orca-t-fda-review-extension-extends-of-bios-for)